Reducing variability through controlled review workflows.
Dixit delivers structured central review and adjudication workflows powered by WIDEN to improve consistency, reproducibility and scientific reliability across multicentre imaging studies.
Interpretative variability impacts clinical endpoints.
In imaging clinical trials, differences between reviewers, interpretation methodologies and review criteria can significantly affect endpoint consistency and statistical outcomes.
Without structured review governance, multicentre studies risk variability that may compromise both scientific reliability and regulatory defensibility.
See our approach
Controlled review environments designed for consistency.
Powered by WIDEN, our central review workflows provide structured and traceable reviewer environments — combining scientific methodology with platform-driven workflow control to improve endpoint reliability across complex studies.
- Blinded independent review. Reads sequenced to protect the integrity of the endpoint.
- Reviewer calibration. Reviewers aligned to study-specific imaging criteria before go-live.
- Adjudication processes. Controlled discrepancy resolution for critical endpoint evaluations.
- Workflow traceability. Audit-ready tracking across every phase of the review lifecycle.
- Operational oversight. Visibility across review timelines, workload and endpoint governance.
Illustrative interface — sample data, not client results.
What our central review workflows include.
A controlled reading model designed around the response criteria your study uses, with traceability at every step.
Independent central review
Structured blinded review workflows for multicentre studies.
Reviewer calibration
Training and alignment programmes based on study-specific imaging criteria.
Adjudication management
Controlled discrepancy resolution processes for critical endpoint evaluations.
Workflow traceability
Audit-ready tracking of reviewer activity, decisions and workflow progression.
Centralised oversight
Operational visibility across review timelines, workload distribution and endpoint governance.
Reliable review processes strengthen clinical development.
Central review should not be a procedural task. It should be a controlled and traceable operational process.
-
Endpoint reproducibility
Consistent interpretation across reviewers, sites and timepoints.
-
Statistical robustness
Reduced interpretative variability supports cleaner statistical outcomes.
-
Operational transparency
Full visibility into reviewer activity, decisions and progression.
-
Regulatory defensibility
An endpoint traceable to a documented, reproducible review process.
Central review, peer-reviewed.
The review process described on this page is the one reported in these papers, in trials run by the FIL and the European Myeloma Network. See all publications.
- Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi (opens in a new tab)
- End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial (opens in a new tab)
- Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results (opens in a new tab)
- PSMA and FDG-PET as predictive and prognostic biomarkers in patients given 177Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial (opens in a new tab)
- Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) (opens in a new tab)
- Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study (opens in a new tab)
- Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) (opens in a new tab)
- WIDEN: A tool for medical image management in multicenter clinical trials (opens in a new tab)
What investigators say about central review.
WIDEN is a great platform to use for imaging in clinical trials. It works across time zones for international trials. As a reporter, it’s easy to access, integrates with my preferred local software and I can easily enter my results. It contacts the Clinician responsible for the patient directly and offers a feature for urgent medical communication. Any issues and I have found the WIDEN team to be very receptive.
Since 2010, the Polish Lymphoma Research Group is an active user of Dixit and their WIDEN platform, that enabled us to start and carry out Observational Study on the role of very early interim PET results during ABVD chemotherapy of patients with Hodgkin Lymphoma. The study requires reviewing of all interim PET studies by the independent Panel of Reviewers. Such a panel, consisting of the Polish and Italian nuclear medicine specialists was established. All reviewers have the access to anonymized PET scans loaded to the WIDEN platform by local PET centers in Poland. The process requires some basic computer skills and is feasible for all even inexperienced users. It allows comparing the concordance between reviewers and identifying cases requiring further discussion. Without WIDEN our study would never gain any scientific value.
The International Extranodal Lymphoma Study Group is using Dixit and the WIDEN platform in several ongoing international clinical trials, in which the timely central review of PET scans is a most critical step. The WIDEN software fully meets our needs and completely fulfills our expectations. WIDEN has become an essential support to our research programs.
Our department is using Dixit and the WIDEN platform in an ongoing international clinical trial, in which the timely central review of PET scans is a most critical step. The WIDEN software fully meets our needs and completely fulfills our expectations. WIDEN has become an essential support to our research programs.
Improve consistency across your imaging endpoints.
Discover how structured review governance powered by WIDEN can support your multicentre clinical study.